Meoli Elise, Bossis Ioannis, Cazabat Laure, Mavrakis Manos, Horvath Anelia, Stergiopoulos Sotiris, Shiferaw Miriam L, Fumey Glawdys, Perlemoine Karine, Muchow Michael, Robinson-White Audrey, Weinberg Frank, Nesterova Maria, Patronas Yianna, Groussin Lionel, Bertherat Jérôme, Stratakis Constantine A
Section on Endocrinology and Genetics, Program in Developmental Endocrinology and Genetics, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland 20892, USA.
Cancer Res. 2008 May 1;68(9):3133-41. doi: 10.1158/0008-5472.CAN-08-0064.
Most PRKAR1A tumorigenic mutations lead to nonsense mRNA that is decayed; tumor formation has been associated with an increase in type II protein kinase A (PKA) subunits. The IVS6+1G>T PRKAR1A mutation leads to a protein lacking exon 6 sequences [R1 alpha Delta 184-236 (R1 alpha Delta 6)]. We compared in vitro R1 alpha Delta 6 with wild-type (wt) R1 alpha. We assessed PKA activity and subunit expression, phosphorylation of target molecules, and properties of wt-R1 alpha and mutant (mt) R1 alpha; we observed by confocal microscopy R1 alpha tagged with green fluorescent protein and its interactions with Cerulean-tagged catalytic subunit (C alpha). Introduction of the R1 alpha Delta 6 led to aberrant cellular morphology and higher PKA activity but no increase in type II PKA subunits. There was diffuse, cytoplasmic localization of R1 alpha protein in wt-R1 alpha- and R1 alpha Delta 6-transfected cells but the former also exhibited discrete aggregates of R1 alpha that bound C alpha; these were absent in R1 alpha Delta 6-transfected cells and did not bind C alpha at baseline or in response to cyclic AMP. Other changes induced by R1 alpha Delta 6 included decreased nuclear C alpha. We conclude that R1 alpha Delta 6 leads to increased PKA activity through the mt-R1 alpha decreased binding to C alpha and does not involve changes in other PKA subunits, suggesting that a switch to type II PKA activity is not necessary for increased kinase activity or tumorigenesis.
大多数PRKAR1A致瘤性突变会导致无义mRNA降解;肿瘤形成与II型蛋白激酶A(PKA)亚基增加有关。IVS6 + 1G>T PRKAR1A突变导致一种缺乏外显子6序列的蛋白质[R1αΔ184 - 236(R1αΔ6)]。我们在体外将R1αΔ6与野生型(wt)R1α进行了比较。我们评估了PKA活性和亚基表达、靶分子的磷酸化以及wt - R1α和突变型(mt)R1α的特性;我们通过共聚焦显微镜观察了标记有绿色荧光蛋白的R1α及其与标记有天蓝荧光蛋白的催化亚基(Cα)的相互作用。引入R1αΔ6导致细胞形态异常和PKA活性升高,但II型PKA亚基没有增加。在wt - R1α和R1αΔ6转染的细胞中,R1α蛋白呈弥漫性细胞质定位,但前者还表现出与Cα结合的R1α离散聚集体;这些在R1αΔ6转染的细胞中不存在,并且在基线或对环磷酸腺苷的反应中不与Cα结合。R1αΔ6诱导的其他变化包括核内Cα减少。我们得出结论,R1αΔ6通过mt - R1α与Cα的结合减少导致PKA活性增加,并且不涉及其他PKA亚基的变化,这表明向II型PKA活性的转变对于增加激酶活性或肿瘤发生不是必需的。